Project description
Innovative resorbable implants for breast reconstruction surgery
Breast tissue modifications and restorations utilise silicone implants, which are associated with significant risks and need replacement every 10-15 years. The alternative fat grafting technique requires multiple interventions for large reconstructions, has been linked to carcinogenic risks and does not promote vascularisation. Italian-based company Tensive has developed a bioabsorbable scaffold based on highly biocompatible polyurethane ester. The patented scaffold provides a synthetic microvascular network that supports adipocyte colonisation in vivo. The unique design enables vascularisation, and the scaffold degrades over time to be replaced by the patient´s fat tissue. The EU-funded REGENERA project aims to bring to market this innovative mammary prosthesis by conducting the first-in-human trial and completing the regulatory requirements for commercialisation.
Objective
Tensive was founded in 2012 to address the challenge of developing better biomaterials for regenerative medicine. We developed a bio absorbable scaffold based on highly biocompatible polyurethaneester. Our patented scaffolds provide a synthetic micro-vascular network that enables adipocytes colonization in vivo. This unique design leads to vascularization, fat integration and volume maintaining after implantation. Based on these unique properties, we will bring to the market REGENERA, an innovative mammary prosthesis that is degraded over time and replaced by the patient´s fat. Silicone implants, the most currently used breast tissue modifications, have important risks and need replacement every 10-15 years. Fat grafting, the best alternative nowadays, has been linked to carcinogenic risks and does not promote vascularization (leading to necrosis) with multiple interventions needed for large reconstructions. REGENERA, which only requires one surgical intervention, will meet the need to develop biomaterials able to promote new blood vessels formation that perpetuate the reconstructed tissue. REGENERA will have a significant impact on various levels: (i) Healthcare system: it will save the cost of additional surgeries (more than €241M yearly in the EU), helping to the sustainability of the Healthcare system. (ii) breast cancer patients: it will offer a solution to lumpectomy patients, for whom there are no good solutions yet; a better alternative for mastectomy and breast augmentation patients; a permanent solution by a single surgery for all patients, improving their quality of life. (iii) company: it will increase Tensive’s revenues (cumulative profit of €257M with a ROI of 19.37 by 2025) (iv) society: it will highly benefit 230,000 women needing reconstructive surgery after breast cancer, together with the 1.35M women undergoing breast augmentation for personal reasons
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences medical biotechnology implants breast implants
- engineering and technology industrial biotechnology biomaterials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20124 Milano
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.